News & Updates
Filter by Specialty:
Show Multimedia Only

Add-on bispecific antibody may alter treatment landscape of G/GEJ cancer
12 Jun 2024
byAudrey Abella
Adding the PD-1/CTLA-4 bispecific antibody cadonilimab to chemotherapy improves overall survival (OS) and progression-free survival (PFS) in individuals with untreated, HER2-negative, locally advanced or metastatic gastric or gastroesophageal junction (G/GEJ) cancer, including patients with PD-L1–low tumours, according to the interim results of the phase III COMPASSION-15 trial.